Get started
Author

Nourdine Kabirou Bah

DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors
2019 · Nisha Pillay, Anthony Tighe, et al. · Cancer Cell · 155
PDF
Lysosomal damage drives mitochondrial proteome remodelling and reprograms macrophage immunometabolism
2022 · Claudio Bussi, Tiaan Heunis, et al. · Nature Communications · 99
PDF
Mesenchymal niche remodeling impairs hematopoiesis via stanniocalcin 1 in acute myeloid leukemia
2020 · Alexander Waclawiczek, Ashley Hamilton, et al. · Journal of Clinical Investigation · 89
PDF
Normality sensing licenses local T cells for innate-like tissue surveillance
2022 · Duncan R. McKenzie, Rosie Hart, et al. · Nature Immunology · 72
Bcl-xL controls a switch between cell death modes during mitotic arrest
2014 · N Bah, L Maillet, et al. · Cell Death and Disease · 72
PDF
Cosmic kidney disease: an integrated pan-omic, physiological and morphological study into spaceflight-induced renal dysfunction
2024 · Keith Siew, Kevin A. Nestler, et al. · Nature Communications · 68
PDF
Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry
2021 · Febe van Maldegem, Karishma Valand, et al. · Nature Communications · 68
PDF
γδ T cells compose a developmentally regulated intrauterine population and protect against vaginal candidiasis
2020 · L. Monin, D.S. Ushakov, et al. · Mucosal Immunology · 59
PDF
Metabolic reprogramming and Notch activity distinguish between non-small cell lung cancer subtypes
2019 · Katherine Sellers, Thaddeus D. Allen, et al. · British Journal of Cancer · 58
PDF
CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2024 · Jesse Boumelha, Andrea de Castro, et al. · Cancer Research · 54
PDF
Regulation of cancer cell survival by BCL2 family members upon prolonged mitotic arrest: opportunities for anticancer therapy.
2012 · Sophie Barillé-Nion, Nourdine Bah, et al. · PubMed · 54
The p38α Stress Kinase Suppresses Aneuploidy Tolerance by Inhibiting Hif-1α
2018 · Susana Simões-Sousa, Samantha Littler, et al. · Cell Reports · 47
PDF
Systematic diet composition swap in a mouse genome-scale metabolic model reveals determinants of obesogenic diet metabolism in liver cancer
2023 · Frederick Clasen, Patrícia M. Nunes, et al. · iScience · 8
Erratum: Bcl-xL controls a switch between cell death modes during mitotic arrest
2014 · N Bah, L Maillet, et al. · Cell Death and Disease · 5
PDF
Developing a functional precision medicine assay to predict pathological complete response in patients with triple-negative breast cancer: Interim results from the PEAR-TNBC Trial
2024 · Peter Hall, Matthew Williams, et al. · medRxiv · 2
Clinical validation of image-based AI predictive biomarkers for precision neoadjuvant triple-negative breast cancer treatment (PEAR-TNBC).
2024 · Matthew Williams, Eleonora Peerani, et al. · Journal of Clinical Oncology · 1
Supplementary Table 2 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2026 · Jesse Boumelha, Andrea de Castro, et al.
Supplementary Figure 8 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2026 · Jesse Boumelha, Andrea de Castro, et al.
Supplementary Figure 6 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2026 · Jesse Boumelha, Andrea de Castro, et al.
Supplementary Table 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2026 · Jesse Boumelha, Andrea de Castro, et al.
Supplementary Figure 7 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2026 · Jesse Boumelha, Andrea de Castro, et al.
Supplementary Figure 4 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2026 · Jesse Boumelha, Andrea de Castro, et al.
Supplementary Figure 3 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2026 · Jesse Boumelha, Andrea de Castro, et al.
Supplementary Table 1 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2026 · Jesse Boumelha, Andrea de Castro, et al.
Supplementary Figure 1 from CRISPR–Cas9 Screening Identifies KRAS-Induced COX2 as a Driver of Immunotherapy Resistance in Lung Cancer
2026 · Jesse Boumelha, Andrea de Castro, et al.
Works count: 64
Citation count: 912
H-index: 12
I10-index: 12
Year
Topic
Type